Showing results (201-210 of 304) with videos related to

Sort By:
Pageof 31
Frontiers in Oncology|October 19, 2020
Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast CancerLorenzo Gerratana, Debora Basile, Alessandra Franzoni, et al.
Breast (Edinburgh, Scotland)|October 2, 2023
Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA studyMassimo Di Maio, Claudia Bighin, Francesco Schettini, et al.
Cancers|June 12, 2026
Adjuvant Therapy for High-Risk Stage II Cutaneous Melanoma: Insights and Future DirectionsFederico Pravisano, Jacopo Costa, Lorenzo De Marchi, et al.
Breast (Edinburgh, Scotland)|April 18, 2026
Integrating PIK3CA Testing into Clinical Practice for Advanced HR+/HER2- Breast Cancer: An Expert ConsensusCarmine De Angelis, Dario de Biase, Lorenzo Gerratana, et al.
British Journal of Cancer|November 2, 2016
The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patientsMatteo Lambertini, Ana Catarina Pinto, Lieveke Ameye, et al.
Future Oncology (London, England)|August 11, 2020
Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancerSilvio Ken Garattini, Marta Bonotto, Luca Porcu, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 20, 2018
Prognostic evaluation in palliative care: final results from a prospective cohort studyPaola Ermacora, Micol Mazzer, Miriam Isola, et al.
Cancer Treatment Reviews|August 20, 2022
Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?Giovanna Garufi, Luisa Carbognin, Concetta Arcanà, et al.
ESMO Open|August 21, 2020
Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort studyEva Blondeaux, Arlindo R Ferreira, Francesca Poggio, et al.
Breast Cancer Research and Treatment|April 6, 2012
Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept studyMarta Pestrin, Silvia Bessi, Fabio Puglisi, et al.
Pageof 31